These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22971686)

  • 21. A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
    Gopi SS; Goodman CM; Robertson A; Byrne DJ
    ScientificWorldJournal; 2006 Jun; 6():2436-41. PubMed ID: 17619714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study.
    Hagiwara K; Koie T; Iwamura H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Ohyama C
    Biomed Res Int; 2016; 2016():4975851. PubMed ID: 27195288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.
    Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K;
    BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention.
    Ghalayini IF; Al-Ghazo MA; Pickard RS
    BJU Int; 2005 Jul; 96(1):93-7. PubMed ID: 15963128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
    Shah T; Palit V; Biyani S; Elmasry Y; Puri R; Flannigan GM
    Eur Urol; 2002 Oct; 42(4):329-32; discussion 332. PubMed ID: 12361896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of combined use of ketoconazole and tamsulosin in management of acute urinary retention due to benign prostatic obstruction (a randomized controlled trial).
    Elbendary M; El-Gamal OM; Soliman MG; Tawfik A; Taha MR
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):362-6. PubMed ID: 24018711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management outcome of acute urinary retention: model of prediction.
    Daly P; Connolly S; Rogers E; Sweeney P
    Urol Int; 2009; 83(1):39-43. PubMed ID: 19641357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saline bladder infusion vs standard catheter removal in patients with acute urinary retention related to benign prostatic hyperplasia: The BLAPERF Study.
    Corral R; Boissier R; Depaquit TL; Gondran-Tellier B; Bastide C; Lechevallier E; Baboudjian M
    Prog Urol; 2023 May; 33(6):319-324. PubMed ID: 36842924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
    Chung SD; Chang HC; Chiu B; Liao CH; Kuo HC
    Neurourol Urodyn; 2011 Apr; 30(4):568-71. PubMed ID: 21344494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
    McNeill SA; Daruwala PD; Mitchell ID; Shearer MG; Hargreave TB
    BJU Int; 1999 Oct; 84(6):622-7. PubMed ID: 10510105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Alpha-adrenergic blockers as a support in the treatment of acute urinary retention].
    Altarac S
    Lijec Vjesn; 2006; 128(7-8):233-7. PubMed ID: 17087140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI; Chang HS; Kim BK; Park CH
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Kaplan SA; Walmsley K; Te AE
    J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors for the success of trial without catheter for men with urinary retention.
    Takanashi M; Ito H; Fukazawa T; Takizawa H; Hioki M; Shinoki R; Kawahara T; Kobayashi K
    Low Urin Tract Symptoms; 2023 Sep; 15(5):173-179. PubMed ID: 37278133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.